Video

Sikarin Upala from Bassett Medical Center: Using Caffeine to Slow Progression of Hepatitis C and Hepatic Fibrosis

A recent study looked to shed light on the long-researched belief that caffeine decreases the risk of advanced hepatic fibrosis in people with hepatitis C.

A recent study looked to shed light on the long-researched belief that caffeine decreases the risk of advanced hepatic fibrosis in people with hepatitis C.

Sikarin Upala, MD, Bassett Medical Center, spoke about using caffeine to slow the progression of Hepatitis C and Hepatic Fibrosis during DDW 2016 in San Diego.

The research aimed to determine if there was any correlation between caffeine intake and hepatitis c infection or liver fibrosis. In the studies, caffeine beverages were consumed, whether one cup or several cups a day.

“We found those in the group who consumed caffeine reduced the risk of chronic Hepatitis C by 61 percent, compared to the group that did not have caffeine consumption,” Upala said.

The risk was specific to those who had hepatitis c and could then have advanced to liver cirrhosis as a result of that risk, he said. “Caffeine also helped improve the liver function of the caffeine group,” he added.

Upala said the research is significant because caffeine is so widely available in food and drink products. He recommended more studies, including randomized control trials, as his research was general data.

Also on MD Magazine >>> More news from Digestive Disease Week 2016

Related Videos
Davide Matino, MD, MSc: Bringing Marstacimab Treatment to Hemophilia A and B
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
© 2024 MJH Life Sciences

All rights reserved.